Newborn screening, early treatment show benefit in SMA type 1

Infants diagnosed with spinal muscular atrophy (SMA) type 1 through newborn screening programs (NBS) and treated early with Spinraza (nusinersen) showed better survival, motor function, milestone achievement, and feeding and breathing independence than infants who began treatment after symptoms appeared, a real-world study in Turkey found. The nationwide study’s findings demonstrate that “timing…